Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Advertising topic
No spam. Unsubscribe anytime.
Senate committee advances Gibson bill to curb misleading ads for compounded weight‑loss drugs
Summary
The committee voted 7‑3 to send AB 19 90 to Senate Judiciary. Sponsors said the bill targets deceptive online ads for compounded GLP‑1 weight‑loss products and would require disclosure that compounds are not FDA‑approved and include risk information; compounding pharmacies warned the measure could create implementation and access problems.
The Senate Business, Professions and Economic Development Committee voted 7‑3 to advance AB 19 90, Assemblymember Gibson’s bill to tighten advertising standards for certain compounded weight‑loss medications.
Gibson said the bill responds to a surge of online ads for compounded GLP‑1 medications that often omit risk information and misleadingly imply equivalence with FDA‑approved products. Supporters including Gabriela Cosell (testifying for Novo Nordisk) and Nancy Glick of the National Consumers League argued consumers often cannot distinguish between FDA‑approved drugs and compounded products and that current ads frequently lack safety disclosures.
Cosell told the committee ads "frequently contain unsubstantiated claims and no information on risks or side effects" and said the bill brings specificity to enforcement so consumers and clinicians see material safety information. Glick said compounded GLP‑1s "are not FDA approved" and warned there have been dosing errors and reactions linked to the market for mass‑market compounded products.
Compounding industry witnesses, including Teneal Davis of the Alliance for Pharmacy Compounding and pharmacist Marie Cotman, said they support truthful disclosures that compounded products are not FDA‑approved but raised practical and legal concerns. Davis and Cotman said requiring pharmacies to use summaries from FDA‑approved labeling for commercially manufactured drugs could create false equivalencies, be infeasible for individualized compounded formulations, and harm patient access during shortages.
Committee members asked whether the bill would inadvertently outlaw advertising by pharmacies or create conflicts with federal labeling rules; supporters said the measure requires targeted disclosures (unapproved status and known risks), not full FDA labeling. Opponents asked who would enforce the rule and whether the bill would reach out‑of‑state telehealth operators. The committee record shows the bill was moved to Senate Judiciary for further review.
The bill will next be considered by Senate Judiciary, where members said they will examine the implementation and enforcement details raised in testimony.
